We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+4.18%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$350M
AUM Growth
+$13.8M
Cap. Flow
+$18M
Cap. Flow %
5.13%
Top 10 Hldgs %
37.4%
Holding
88
New
31
Increased
19
Reduced
18
Closed
19

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$9.29M
2
DHR icon
Danaher
DHR
+$9.16M
3
ZBH icon
Zimmer Biomet
ZBH
+$8.78M
4
NTLA icon
Intellia Therapeutics
NTLA
+$7.38M
5
MRK icon
Merck
MRK
+$6.96M

Top Sells

Rank Stock Value
1
ABT icon
Abbott
ABT
+$8.76M
2
LLY icon
Eli Lilly
LLY
+$8.44M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$8.37M
4
NVRO
NEVRO CORP.
NVRO
+$7.83M
5
ABBV icon
AbbVie
ABBV
+$7.5M

Sector Composition

Rank Sector Weight
1 Healthcare 91.97%
2 Energy 3%
3 Industrials 0.97%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACHC icon
1
Acadia Healthcare
ACHC
$2.85B
$19.7M 5.63%
345,000
+30,000
+10% +$1.62M
CYTK icon
2
Cytokinetics
CYTK
$10.4B
$16.3M 4.65%
700,000
+175,000
+33% +$3.74M
ARNA
3
DELISTED
Arena Pharmaceuticals Inc
ARNA
$14.6M 4.16%
210,000
+10,000
+5% +$769K
NVST icon
4
Envista
NVST
$4.45B
$14.1M 4.02%
345,000
+25,000
+8% +$953K
NTLA icon
5
Intellia Therapeutics
NTLA
$1.58B
$13.6M 3.9%
170,000
+110,000
+183% +$7.38M
BPMC
6
DELISTED
Blueprint Medicines
BPMC
$11.4M 3.26%
117,500
+32,500
+38% +$3.24M
SAGE
7
DELISTED
Sage Therapeutics
SAGE
$10.8M 3.08%
144,000
-51,000
-26% -$4.18M
LHCG
8
DELISTED
LHC Group LLC
LHCG
$10.5M 3%
55,000
-13,000
-19% -$2.6M
CRL icon
9
Charles River Laboratories
CRL
$11.1B
$10.1M 2.9%
35,000
-18,000
-34% -$5M
MCK icon
10
McKesson
MCK
$96.8B
$9.75M 2.79%
50,000
-5,000
-9% -$913K
CNC icon
11
Centene
CNC
$31.5B
$9.59M 2.74%
+150,000
New +$9.29M
DHR icon
12
Danaher
DHR
$139B
$9M 2.57%
+45,120
New +$9.16M
ZBH icon
13
Zimmer Biomet
ZBH
$18.5B
$8.8M 2.52%
+56,650
New +$8.78M
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.56M 2.45%
50,000
+13,000
+35% +$2.57M
CCXI
15
DELISTED
ChemoCentryx, Inc.
CCXI
$7.94M 2.27%
155,000
-25,000
-14% -$1.5M
MRK icon
16
Merck
MRK
$316B
$6.94M 1.98%
+94,320
New +$6.96M
RVTY icon
17
Revvity
RVTY
$12.4B
$6.42M 1.83%
50,000
-15,000
-23% -$2.08M
LH icon
18
Labcorp
LH
$24.9B
$6.38M 1.82%
+29,100
New +$5.84M
AERI
19
DELISTED
Aerie Pharmaceuticals
AERI
$6.25M 1.79%
350,000
+150,000
+75% +$2.59M
ZLAB icon
20
Zai Lab
ZLAB
$2.05B
$6M 1.72%
45,000
+15,000
+50% +$2.32M
MDT icon
21
Medtronic
MDT
$110B
$5.91M 1.69%
50,000
+15,000
+43% +$1.76M
ALNY icon
22
Alnylam Pharmaceuticals
ALNY
$29.5B
$5.65M 1.61%
40,000
+25,000
+167% +$3.76M
NVRO
23
DELISTED
NEVRO CORP.
NVRO
$5.58M 1.59%
40,000
-48,000
-55% -$7.83M
MGNX icon
24
MacroGenics
MGNX
$243M
$5.57M 1.59%
175,000
+85,000
+94% +$2.06M
DNLI icon
25
Denali Therapeutics
DNLI
$3.84B
$5.54M 1.58%
97,000
+39,500
+69% +$2.64M
1
2 3 4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
NSCM
New South Capital Management Memphis, Tennessee $2.09B AUM 33.67% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return

Integral Health Asset Management's Q1 2021 Portfolio in Review

As of Q1 2021, Integral Health Asset Management held 88 positions worth $350M, up 4.1% from $336M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Integral Health Asset Management deployed $18M of net new capital in Q1 2021, opening 31 new positions and adding to 19 existing holdings. Its largest new stake was Centene: 150,000 shares worth $9.59M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier, followed by Energy and Industrials.

On the sell side, the largest reduction was NEVRO CORP., an estimated $7.83M trimmed.

  • Integral Health Asset Management's largest Q1 2021 buy was Centene: 150,000 shares worth $9.59M.
  • Integral Health Asset Management added most to Intellia Therapeutics in Q1 2021, an estimated $7.38M increase.
  • Integral Health Asset Management's biggest Q1 2021 reduction was NEVRO CORP., cutting an estimated $7.83M.
  • Integral Health Asset Management fully exited Abbott in Q1 2021, selling an estimated $8.76M.
  • Integral Health Asset Management's ten largest holdings make up 37% of its $350M portfolio in Q1 2021.
  • Integral Health Asset Management opened 31 new positions and closed 19 in Q1 2021.
  • Integral Health Asset Management's portfolio value rose 4.1% quarter-over-quarter to $350M.

Based on Integral Health Asset Management's 13F filing for Q1 2021, filed 10 May 2021.